The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection
NCT05620602 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 628
Last updated 2022-11-17
Summary
The researchers collect patients who accepted eradication program of the helicobacter pylori but failed to eradicate helicobacter pylor from the outpatient clinic. After rescue therapy, evaluating the effect of retreatment interval on eradication effect of Helicobacter pylori infection.
Conditions
- Helicobacter Pylori Infection
Interventions
- OTHER
-
Remedial treatment within 3 months
The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.
- OTHER
-
Remedial treatment within 3 to 6 months
The interval between the time of this treatment and the last day of the last therapy is 3-6 months. Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.
- OTHER
-
Remedial treatment within 6 to 12 months
The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.
- OTHER
-
Remedial treatment after 12 months
The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d. Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.
Sponsors & Collaborators
-
Peking University Care Luzhong Hospital
collaborator OTHER -
Yuncheng Traditional Chinese Medicine Hospital
collaborator OTHER -
Taierzhuang District People's Hospital
collaborator OTHER -
Zhengzhou Central Hospital
collaborator OTHER -
Zibo Central Hospital
collaborator OTHER_GOV -
Shandong University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-11
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection
NCT05126121 ·Status: UNKNOWN ·Phase: NA
-
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
NCT02934048 ·Status: UNKNOWN ·Phase: PHASE4
-
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
NCT05176821 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302)
NCT05997433 ·Status: RECRUITING ·Phase: NA
-
Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection
NCT05718609 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection
NCT03658746 ·Status: COMPLETED ·Phase: PHASE4
-
Helicobacter Pylori Eradication and Follow-up
NCT05061732 ·Status: RECRUITING ·Phase: PHASE4
-
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection
NCT03565484 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
NCT02359331 ·Status: TERMINATED ·Phase: NA
-
Study the Effect of Probiotics Combined With Bismuth Quadruple Rescue Therapy on H Pylori Infective Patients
NCT03297242 ·Status: UNKNOWN
-
Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication
NCT06723197 ·Status: RECRUITING ·Phase: PHASE4
-
Tailored Therapy for Helicobacter Pylori Rescue Treatment
NCT03413020 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT03726099 ·Status: UNKNOWN ·Phase: PHASE4
-
Rescue Therapy for Helicobacter Pylori Infection
NCT05874544 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection
NCT05133193 ·Status: UNKNOWN ·Phase: NA
-
A Multi-center Study for Eradication of Refractory Helicobacter Pylori
NCT02741414 ·Status: UNKNOWN ·Phase: NA
-
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
NCT05332444 ·Status: RECRUITING ·Phase: PHASE4
-
Community-based Helicobacter Pylori Eradication
NCT00155389 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment
NCT06292546 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
NCT07333001 ·Status: COMPLETED
-
Empirical Rescue Therapies of Helicobacter Pylori Infection
NCT01668927 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT04991584 ·Status: UNKNOWN ·Phase: NA
-
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
NCT05250050 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy
NCT01265069 ·Status: UNKNOWN ·Phase: PHASE4
-
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
NCT03365609 ·Status: RECRUITING ·Phase: NA